Immunocore Holdings (IMCR) Operating Expenses (2023 - 2026)

Immunocore Holdings has disclosed Operating Expenses across 4 years of filings, most recently posting $99.0 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $99.0 million, up 2.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $442.6 million (up 17.13% YoY), and the FY2025 annual result was $440.3 million, up 16.5% from the prior year.
• Operating Expenses came in at $99.0 million for Q1 2026 at Immunocore Holdings, down from $121.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $121.5 million in Q4 2025 to a low of $69.1 million in Q1 2023.
• The 4-year median for Operating Expenses is $96.7 million (2025), against an average of $94.2 million.
• Across the five-year window, Operating Expenses jumped 39.93% in 2024 and decreased 0.08% in 2025, its largest moves.
• Immunocore Holdings' Operating Expenses stood at $87.0 million in 2023, then increased by 18.57% to $103.2 million in 2024, then advanced by 17.73% to $121.5 million in 2025, then declined by 18.53% to $99.0 million in 2026.
• The last three Operating Expenses figures came in at $99.0 million (Q1 2026), $121.5 million (Q4 2025), and $110.4 million (Q3 2025), per Business Quant data.